Biosimilars Blog
RF 360
Erin Foley*, Ph.D. Associate

Erin Foley is experienced in a wide variety of patent law matters, including patent prosecution, litigation, patent portfolio evaluations, opinions, and counseling. She routinely handles many aspects of patent prosecution, from pre-application counseling, to application preparation, worldwide filings, and prosecution. She also handles many aspects of patent litigation, including counseling as to the scope, validity and enforceability of rights of existing patents. Since joining Rothwell Figg in 2013, she has worked closely with the firm's clients in the small molecule, antibody engineering, biologics, biotechnology, genetic engineering, and glass technology spaces.

During her doctoral studies at the University of California San Diego, Dr. Foley studied the endocytic clearance of triglyceride-rich lipoproteins by the hepatic heparan sulfate proteoglycan syndecan-1. Dr. Foley earned her J.D. in the part-time program at the Georgetown University Law Center, where she was awarded the ABA/BNA Award for Excellence in Intellectual Property Law, and she holds an undergraduate degree in Biochemistry from the University of California, Los Angeles.

*Not admitted to the DC Bar

Publications & Presentations

Foley, E.M., Gordts, P.L., Stanford, K.I., Gonzales, J.C., Lawrence, R., Stoddard, N., Esko, J.D. Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice. Atherosclerosis, Thrombosis, and Vascular Biology (2013). 33:2065-74.

Zaiss, A.K., Foley, E.M., Lawrence, R., Schneider, L.S., Hoveida, H., Secrest, P., Catapang, A.B., Yamaguchi, Y., Alemany, R., Shayakhmetov, D.M., Esko, J.D., Herschman, H.R. Hepatocyte Heparan Sulfate is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo. Journal of Virology (2015). 90:412-20.

Mooj, H.L., Bernelot Moens, S.J., Gordts, P.L., Stanford, K. I., Foley, E.M., ven den Boogert, M.A., Witjes, J.J., Hassing, H.C., Tanck, M.W., van de Sande, M.A., Levels, J.H., Kastelein, J.J., Stroes, E.S., Dallinga-Thie, G.M., Esko, J.D., Nieuwdorp, M. Ext 1 heterozygosity causes a modest effect on postprandial lipid clearance in humans. Journal of Lipid Research (2015). 56:665-73.
Gordts, P.L., Foley, E.M., Lawrence, R., Sinha, R., Lameda-Diaz, C., Deng, L., Nock, R., Glass, C.K., Erbilgin, A., Lusis, A.J., Witztum, J.L., Esko, J.D. Reducing macrophage proteoglycan sulfation increases atherosclerosis and obesity through enhanced type I interferon signaling. Cell Metabolism (2014). 20:813-26.

Gonzales, J.C., Gordts, P.L., Foley, E.M., Esko, J.D. Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. The Journal of Clinical Investigation (2013). 123:2742-51.

Deng, Y., Foley, E.M., Gonzales, J.C., Gordts, P.L., Li, Y., and Esko, J.D. Shedding of syndecan-1 from human hepatocytes alters VLDL clearance. Hepatology (2012). 55:277-86.

Foley, E.M., and Esko, J.D. Hepatic heparan sulfate proteoglycans and endocytic clearance of triglyceride-rich lipoproteins. Progress in Molecular Biology and Translational Science (2010). 93:213-33.

Bishop, J.R., Foley, E., Lawrence, R., and Esko, J.D. Insulin-dependent diabetes mellitus in mice does not alter liver heparan sulfate. The Journal of Biological Chemistry (2010). 285:14658-62.

Stanford, K.I., Bishop, J.R., Foley, E.M., Gonzales, J.C., Niesman, I.R., Witztum, J.L., and Esko, J.D. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. The Journal of Clinical Investigation (2009). 119:3236-45.